Pharm
Dimethyl Fumarate
search
Dimethyl Fumarate
, Tecfidera
Background
Gene
ric in 2020
Indications
Multiple Sclerosis
(relapsing)
Mechanism
Dimethyl Fumarate key effects
Immunosuppressant
that decreases CD8 T Cells as well as
Cytokine
production
Dimethyl Fumarate effects are neuroprotective and immunomodulating
Dimethyl Fumarate is orally
Bioavailable
Converted in vivo to active metabolite monomethyl fumarate (MMF)
Monomethyl fumarate (MMF)
MMF binds and activates nuclear factor erythroid 2 (NF-E2) and nuclear related factor 2 (Nrf2)
Nuclear related factor 2 (Nrf2)
Nrf2 on activation, translocates to the nucleus and binds antioxidant response element (ARE)
Triggers a cascade of expression of cytoprotective genes
Medications
Dimethyl Fumarate (Tecfidera) Delayed-release capsules: 120 mg and 240 mg
Dosing
Adults
Start: 120 mg orally twice daily for 7 days
Maintenance: 240 mg orally twice daily
If not tolerated, may decrease dose to 120 mg orally twice daily for 4 weeks, then retrial higher dose
Adverse Effects
Serious
Anaphylaxis
or
Angioedema
Progressive Multifocal Leukoencephalopathy
(PML)
Opportunistic infections (e.g.
Herpes Zoster
)
Gastrointestinal
Abdominal Pain
Diarrhea
Nausea
Hematologic
Lymph
openia
Hepatotoxicity
Elevated liver transaminases
Cardiovascular
Flushing
(common)
Decreases over time
Consider taking with food and pretreating with
Aspirin
30 min before dose
Safety
Unknown safety in pregnancy
Toxicity demonstrated in animals
Unknown safety in
Lactation
Monitoring
Complete Blood Count
(at baseline and every 6 months)
Liver Function Test
s (at baseline and periodically)
MRI Brain
(for signs of PML)
Consider yearly testing for JCV Antibodies
Efficacy
Compared with other oral agents for MS
Better tolerated than
Fingolimod
May be more effective than
Teriflunomide
Resources
Dimethyl Fumarate (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6c42107a-2a42-4263-97b6-ae0d7675c92a
Type your search phrase here